



**VIRTUAL/TELECONFERENCE
CONTROLLED SUBSTANCES BOARD
Virtual, 4822 Madison Yards Way, Madison
Contact: Tom Ryan (608) 266-2112
May 8, 2026**

The following agenda describes the issues that the Board plans to consider at the meeting. At the time of the meeting, items may be removed from the agenda. Please consult the meeting minutes for a record of the actions of the Board.

AGENDA

10:00 A.M.

OPEN SESSION – CALL TO ORDER – ROLL CALL

A. Adoption of Agenda (1-3)

B. Approval of Minutes of March 13, 2026 (4-5)

C. Reminders: Conflicts of Interest, Scheduling Concerns

D. Introductions, Announcements and Recognition

E. Administrative Matters – Discussion and Consideration

1. Department, Staff and Board Updates
2. Board Members – Term Expiration Dates
 - a. Barman, Subhadeep – 5/1/2019
 - b. Bellay, Yvonne – DATCP Representative
 - c. Eberhardy, Cullen – AG Representative
 - d. Englebert, Doug – DHS Representative
 - e. Gundersen, David – Dentistry Examining Board Representative
 - f. Jarrett, Jennifer L. – Physician Assistant Affiliated Credentialing Board Representative
 - g. Kane, Amanda – Board of Nursing Representative
 - h. Majeed-Haqqi, Lubna – Medical Examining Board Representative
 - i. Olsen, Christopher M. – Pharmacologist Representative
 - j. Weitekamp, John – Pharmacy Examining Board Representative
3. Alternates
 - a. Alton, Troy – Dentistry Examining Board Representative
 - b. Leuthner, Steven – Medical Examining Board Representative
 - c. Weinman, Robert – Board of Nursing Representative

F. Administrative Rule Matters – Discussion and Consideration (6-13)

1. Affirmative Action Order:
 - a. CSB 2.018, Relating to Scheduling Bromazolam (7)
 - b. CSB 2.019, Relating to Scheduling 3-methoxyphencyclidine (8)

2. Scope Statement
 - a. CSB 2.016, Relating to Scheduling 4-chlormethcathinone (9-10)
 - b. CSB 2.017, Relating to Scheduling 4-fluoroamphetamine (11-12)
3. Pending or Possible Rulemaking Projects
 - a. Rule Projects Chart (13)

G. Prescription Drug Monitoring Program (PDMP) Updates – Discussion and Consideration (14-23)

1. WI ePDMP Operations
 - a. Recent and Upcoming Releases
 - b. EHR Integration Status
2. WI PDMP Outreach

H. DSPS Interdisciplinary Advisory Committee Liaison Report – Discussion and Consideration

I. Board Member Reports – Discussion and Consideration

1. Medical Examining Board
2. Dentistry Examining Board
3. Board of Nursing
4. Pharmacy Examining Board
5. Physician Assistant Affiliated Credentialing Board

J. Report from the Referral Criteria Work Group – Discussion and Consideration

K. Liaison Reports

L. Deliberation on Special Use Authorizations – Discussion and Consideration

M. Discussion and Consideration of Items Added After Preparation of Agenda:

1. Introductions, Announcements, and Recognition
2. Administrative Matters
3. Election of Officers
4. Appointment of Liaisons and Alternates
5. Delegation of Authorities
6. Informational Items
7. Division of Legal Services and Compliance (DLSC) Matters
8. Education and Examination Matters
9. Credentialing Matters
10. Practice Matters
11. Legislative and Administrative Rule Matters
12. Liaison Reports
13. Public Health Emergencies
14. Appearances from Requests Received or Renewed
15. Speaking Engagements, Travel, or Public Relations Requests, and Reports
16. Consulting with Legal Counsel

N. Public Comments

CONVENE TO CLOSED SESSION to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider individual histories or disciplinary data (s. 19.85(1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.).

O. Consulting with Legal Counsel

RECONVENE TO OPEN SESSION IMMEDIATELY FOLLOWING CLOSED SESSION

P. Vote on Items Considered or Deliberated Upon in Closed Session if Voting is Appropriate

Q. Open Session Items Noticed Above Not Completed in the Initial Open Session

ADJOURNMENT

NEXT MEETING: JULY 10, 2026

MEETINGS AND HEARINGS ARE OPEN TO THE PUBLIC, AND MAY BE CANCELLED WITHOUT NOTICE.

Times listed for meeting items are approximate and depend on the length of discussion and voting. All meetings are held virtually unless otherwise indicated. In-person meetings are typically conducted at 4822 Madison Yards Way, Madison, Wisconsin, unless an alternative location is listed on the meeting notice. In order to confirm a meeting or to request a complete copy of the board's agenda, please visit the Department website at <https://dsps.wi.gov>. The board may also consider materials or items filed after the transmission of this notice. Times listed for the commencement of any agenda item may be changed by the board for the convenience of the parties. The person credentialed by the board has the right to demand that the meeting at which final action may be taken against the credential be held in open session. Requests for interpreters for the hard of hearing, or other accommodations, are considered upon request by contacting the Affirmative Action Officer or reach the Meeting Staff by calling 608-267-7213.

**VIRTUAL/TELECONFERENCE
CONTROLLED SUBSTANCES BOARD
MEETING MINUTES
MARCH 13, 2026**

PRESENT: Yvonne Bellay, Cullen Eberhardy, Doug Englebert, Jennifer Jarrett, Amanda Kane, Lubna Majeed-Haqqi, Christopher Olsen; John Weitekamp

ABSENT: Subhadeep Barman, David Gundersen

STAFF: Tom Ryan, Executive Director; Jameson Whitney, Legal Counsel; Nilajah Hardin, Administrative Rules Coordinator; Tracy Drinkwater, Board Administrative Specialist; and other DSPS Staff

CALL TO ORDER

Doug Englebert, Chairperson, called the meeting to order at 10:00 a.m. A quorum was confirmed with eight (8) members present.

ADOPTION OF AGENDA

MOTION: Jennifer Jarrett moved, seconded by Cullen Eberhardy, to adopt the Agenda as published. Motion carried unanimously.

APPROVAL OF MINUTES OF JANUARY 23, 2026

MOTION: Cullen Eberhardy moved, seconded by Yvonne Bellay, to adopt the Minutes of January 23, 2026, as published. Motion carried unanimously.

ADMINISTRATIVE RULE MATTERS

Affirmative Action Order

CSB 2.017, Relating to Scheduling 4-fluoroamphetamine

MOTION: John Weitekamp moved, seconded by Yvonne Bellay, to approve the affirmative action order adding 4-fluoroamphetamine as a schedule I controlled substance. The order shall take effect upon publication in the Administrative Register. Motion carried unanimously.

Preliminary Rule Draft

CSB 2.013, Relating to Scheduling Dipentylone

MOTION: Doug Englebert moved, seconded by Christopher Olsen, to approve the preliminary rule draft of CSB 2.013, Relating to Scheduling Dipentylone, for posting for economic impact comments and submission to the Clearinghouse. Motion carried unanimously.

CSB 2.014, Relating to Scheduling 2 Synthetic Benzimidazole-Opioids

MOTION: Yvonne Bellay moved, seconded by Cullen Eberhardy, to approve the preliminary rule draft of CSB 2.014, Relating to Scheduling 2 Synthetic Benzimidazole-Opioids, for posting for economic impact comments and submission to the Clearinghouse. Motion carried unanimously.

Final Rule Draft

CSB 2.012, Relating to Scheduling 7 Fentanyl-related Substances


MOTION: John Weitekamp moved, seconded by Jennifer Jarrett, to approve the Legislative Report and Draft for Clearinghouse Rule Clearinghouse Rule 25-094 (CSB 2.012), Relating to Scheduling 7 Fentanyl-related Substances for submission to the Governor's Office for approval, notification to the Legislature, and approval of the Adoption Order to the Legislative Reference Bureau for publication. Motion carried unanimously.

ADJOURNMENT

MOTION: Yvonne Bellay moved, seconded by John Weitekamp, to adjourn the meeting. Motion carried unanimously.

The meeting adjourned at 10:37 a.m.

**State of Wisconsin
Department of Safety & Professional Services
AGENDA REQUEST FORM**

1) Name and title of person submitting the request: Nilajah Hardin Administrative Rules Coordinator		2) Date when request submitted: 4/28/26 <small>Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting</small>	
3) Name of Board, Committee, Council, Sections: Controlled Substances Board			
4) Meeting Date: 5/08/26	5) Attachments: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	6) How should the item be titled on the agenda page? Administrative Rule Matters – Discussion and Consideration 1. Affirmative Action Order: a. CSB 2.018, Relating to Scheduling Bromazolam b. CSB 2.019, Relating to Scheduling 3-methoxyphenylcyclidine 2. Scope Statement: a. CSB 2.016, Relating to Scheduling 4-chlormethcathinone b. CSB 2.017, Relating to Scheduling 4-fluoroamphetamine 3. Pending or Possible Rulemaking Projects a. Rule Projects Chart	
7) Place Item in: <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session	8) Is an appearance before the Board being scheduled? <i>(If yes, please complete Appearance Request for Non-DSPS Staff)</i> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	9) Name of Case Advisor(s), if required: N/A	
10) Describe the issue and action that should be addressed: Review and take action on Scope Statement, Preliminary Rules Drafts, and Final Rule Drafts. Attachments: <ul style="list-style-type: none"> • Affirmative Action Order – CSB 2.018 and 2.019 • Scope Statement – CSB 2.016 and 2.017 • Rule Projects Chart (All Board Rule Projects can be Viewed Here if Needed: https://dsps.wi.gov/Pages/RulesStatutes/PendingRules.aspx)			
11) Authorization			
 Signature of person making this request		4/28/26 Date	
Supervisor (if required)		Date	
Executive Director signature (indicates approval to add post agenda deadline item to agenda) Date			
Directions for including supporting documents: 1. This form should be attached to any documents submitted to the agenda. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING	:	AFFIRMATIVE ACTION
PROCEEDINGS BEFORE THE	:	ORDER OF THE
CONTROLLED SUBSTANCES BOARD	:	CONTROLLED SUBSTANCES BOARD

FINDINGS

1. On March 16, 2026, the Department of Justice, Drug Enforcement Administration published its temporary rule in the Federal Register listing Bromazolam in schedule I of the federal Controlled Substances Act. The rule was effective March 16, 2026.
2. The Controlled Substances Board did not receive an objection to similarly listing Bromazolam in schedule I under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing Bromazolam as a schedule I controlled substance.
3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.13 and omitting the notice of proposed rulemaking, listing Bromazolam as a schedule I controlled substance.

ORDER

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats Bromazolam under chapter 961, Stats. by creating the following:

CSB 2.018 Addition of Bromazolam to Schedule I. (1) Sections 961.14.(5) (aa), (ab), (ac), (ad), (ae), (ag), (am), and (b) are renumbered to 961.14 (5) (bm), (cm), (dm), (em), (fm), (gm), (hm), and (im).

(2) Section 961.14 (5) (an), Stats., is created to read:

961.14 (5) (an) Bromazolam (8-bromo-1-methyl-6-phenyl-4H-benzol[f][1, 2, 4]triazolo[4,3-a][1, 4]diazepene).

This order shall become effective upon publication in the Administrative Register. The order expires upon promulgation of a final rule.

Dated _____

Doug Englebert, Chairperson
Controlled Substances Board

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING	:	AFFIRMATIVE ACTION
PROCEEDINGS BEFORE THE	:	ORDER OF THE
CONTROLLED SUBSTANCES BOARD	:	CONTROLLED SUBSTANCES BOARD

FINDINGS

1. On March 23, 2026, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing 3-methoxyphencyclidine in schedule I of the federal Controlled Substances Act. The rule is effective as of April 22, 2026.
2. The Controlled Substances Board did not receive an objection to similarly listing 3-methoxyphencyclidine in schedule I under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing 3-methoxyphencyclidine as a schedule I controlled substance.
3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.13 and omitting the notice of proposed rulemaking, listing 3-methoxyphencyclidine as a schedule I controlled substance.

ORDER

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats 3-methoxyphencyclidine under chapter 961, Stats. by creating the following:

CSB 2.019 Addition of 3-methoxyphencyclidine to Schedule I. Section 961.14 (4) (xc), Stats., is created to read:

961.14 (4) (xc). 3-methoxyphencyclidine, commonly known as 3-MeO-PCP.

This order shall become effective upon publication in the Administrative Register. The order expires upon promulgation of a final rule.

Dated _____

Doug Englebort, Chairperson
Controlled Substances Board

STATEMENT OF SCOPE

CONTROLLED SUBSTANCES BOARD

Rule No.: CSB 2.016

Relating to: Scheduling 4-chloromethcathinone

Rule Type: Permanent

1. Finding/nature of emergency: N/A

2. Detailed description of the objective of the proposed rule:

The objective of the proposed rule is to add 4-chloromethcathinone to schedule I under ch. 961, Stats.

3. Description of the existing policies relevant to the rule, new policies proposed to be included in the rule, and an analysis of policy alternatives:

On November 17, 2025, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing 4-chloromethcathinone in schedule I of the federal Controlled Substances Act. The rule is effective as of December 17, 2025. The Controlled Substances Board did not receive an objection to similarly listing 4-chloromethcathinone in schedule I under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing 4-chloromethcathinone as a schedule I controlled substance. Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats 4-chloromethcathinone under chapter 961, Stats. by creating the following:

CSB 2.016 Addition of 4-chloromethcathinone to Schedule I. Section 961.14 (7) (L) 42., Stats., is created to read:

961.14 (7) (L) 42. 1-(4-chlorophenyl)-2-(methylamino)propan-1-one, commonly known as 4-chloromethcathinone, or 4-CMC.

This order shall become effective upon publication in the Administrative Register. The order expires upon promulgation of a final rule.

4. Detailed explanation of statutory authority for the rule:

Section 961.11 (1), Stats. provides that “[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227.”

Section 961.11(4), Stats. provides that “[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30-day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall

Rev. 3/6/2012

publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2).”

5. Estimate of amount of time that state employees will spend developing the rule and of other resources necessary to develop the rule:

Approximately 80 hours.

6. List with description of all entities that may be affected by the proposed rule:

Law enforcement, district attorney offices, Dept of Justice, state courts and the Controlled Substances Board.

7. Summary and preliminary comparison with any existing or proposed federal regulation that is intended to address the activities to be regulated by the proposed rule:

On November 17, 2025, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing 4-chloromethcathinone in schedule I of the federal Controlled Substances Act. The rule is effective as of December 17, 2025.

8. Anticipated economic impact of implementing the rule: None to minimal.

Contact Person: Nilajah Hardin, Administrative Rules Coordinator, DSPSAdminRules@wisconsin.gov

Approved for publication:

Approved for implementation:

Authorized Signature

Authorized Signature

Date Submitted

Date Submitted

STATEMENT OF SCOPE

CONTROLLED SUBSTANCES BOARD

Rule No.: CSB 2.017

Relating to: Scheduling 4-fluoroamphetamine

Rule Type: Permanent

1. Finding/nature of emergency: N/A

2. Detailed description of the objective of the proposed rule:

The objective of the proposed rule is to add 4-fluoroamphetamine to schedule I under ch. 961, Stats.

3. Description of the existing policies relevant to the rule, new policies proposed to be included in the rule, and an analysis of policy alternatives:

On January 15, 2026, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing 4-fluoroamphetamine in schedule I of the federal Controlled Substances Act. The rule is effective as of February 17, 2026. The Controlled Substances Board did not receive an objection to similarly listing 4-fluoroamphetamine in schedule I under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing 4-fluoroamphetamine as a schedule I controlled substance. Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats 4-fluoroamphetamine under chapter 961, Stats. by creating the following:

CSB 2.017 Addition of 4-fluoroamphetamine to Schedule I. Section 961.14 (7) (v), Stats., is created to read:

961.14 (7) (v). 1-(4-fluorophenyl)propan-2-amine, commonly known as 4-fluoroamphetamine, para-fluoroamphetamine, or 4-FA.

This order shall become effective upon publication in the Administrative Register. The order expires upon promulgation of a final rule.

4. Detailed explanation of statutory authority for the rule:

Section 961.11 (1), Stats. provides that “[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227.”

Section 961.11(4), Stats. provides that “[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30-day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the

treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2).”

5. Estimate of amount of time that state employees will spend developing the rule and of other resources necessary to develop the rule:

Approximately 80 hours.

6. List with description of all entities that may be affected by the proposed rule:

Law enforcement, district attorney offices, Dept of Justice, state courts and the Controlled Substances Board.

7. Summary and preliminary comparison with any existing or proposed federal regulation that is intended to address the activities to be regulated by the proposed rule:

On January 15, 2026, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing 4-fluoroamphetamine in schedule I of the federal Controlled Substances Act. The rule is effective as of February 17, 2026.

8. Anticipated economic impact of implementing the rule: None to minimal.

Contact Person: Nilajah Hardin, Administrative Rules Coordinator, DSPSAdminRules@wisconsin.gov

Approved for publication:

Approved for implementation:

Authorized Signature

Authorized Signature

Date Submitted

Date Submitted

**Controlled Substances Board
Rule Projects (updated 4/28/26)**

CH Rule Number	Scope Number	Scope Expiration Date	Code Chapter Affected	Relating Clause	Stage of Rule Process	Next Step
25-094	055-25	02/25/2028	CSB 2.011 (Renumbered to 2.012)	Scheduling 7 Fentanyl-related Substances	Adoption Order Ready for Publication	Submission to Legislature and for Publication; Rule Effective Date TBD
Not Assigned Yet	002-26	07/12/2028	CSB 2.013	Scheduling Dipentylone	EIA Comment Period	Clearinghouse Review
Not Assigned Yet	003-26	07/12/2028	CSB 2.014	Scheduling 2 Synthetic Benzimidazole- Opioids	EIA Comment Period	Clearinghouse Review
Not Assigned Yet	023-26	10/20/2028	CSB 2.015	Scheduling 7 Synthetic Benzimidazole- Opioids	Scope Statement Published on 4/20/26	Scope Implementation
Not Assigned Yet	Not Assigned Yet	TBD	CSB 2.016	Scheduling 4-Chloromethcathinone	Scope Statement Reviewed at 5/8/26 Meeting	Governor's Office Approval and Publication (Preliminary Public Hearing likely to be Ordered by JCRAR)
Not Assigned Yet	Not Assigned Yet	TBD	CSB 2.017	Scheduling 4-Fluoroamphetamine	Scope Statement Reviewed at 5/8/26 Meeting	Governor's Office Approval and Publication (Preliminary Public Hearing likely to be Ordered by JCRAR)
Not Assigned Yet	Not Assigned Yet	TBD	CSB 2.018	Scheduling Bromazolam	Affirmative Action Order Reviewed at 5/8/26 Meeting	Affirmative Action Order Submission for Publication and Drafting of Scope Statement
Not Assigned Yet	Not Assigned Yet	TBD	CSB 2.019	Scheduling 3-methoxyphencyclidine	Affirmative Action Order Reviewed at 5/8/26 Meeting	Affirmative Action Order Submission for Publication and Drafting of Scope Statement

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and title of person submitting the request: Marjorie Liu Program Lead, PDMP		2) Date when request submitted: 04/28/2026 <small>Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting</small>	
3) Name of Board, Committee, Council, Sections: Controlled Substances Board			
4) Meeting Date: 05/08/2026	5) Attachments: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	6) How should the item be titled on the agenda page? Prescription Drug Monitoring Program (PDMP) Updates – Discussion and Consideration	
7) Place Item in: <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session	8) Is an appearance before the Board being scheduled? <i>(If yes, please complete Appearance Request for Non-DSPP Staff)</i> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	9) Name of Case Advisor(s), if required:	
10) Describe the issue and action that should be addressed: 1. WI ePDMP Operations a. Recent and Upcoming Releases b. EHR Integration Status 2. WI PDMP Outreach			
11)	Authorization <i>Marjorie Liu</i>	Date 4/28/2026	
Signature of person making this request		Date	
Supervisor (if required)		Date	
Executive Director signature (indicates approval to add post agenda deadline item to agenda)		Date	
Directions for including supporting documents: 1. This form should be attached to any documents submitted to the agenda. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			

2024-2026 Development and Release Summary

Updated 4.27.2026

Release Date	Description
<p>R33.30 April 2026</p>	<p>DEA -> NPI Systemic Changeover</p> <ul style="list-style-type: none"> • Prescriber Metrics updates • Adding prescriber and pharmacy NPI field to reports • Medical Coordinator user interface updates <p>Public Facing Webpage Updates</p> <ul style="list-style-type: none"> • Dashboard: Top 15 Monitored Prescription Drugs Dispensed • Dashboard: Patients with Monitored Prescription Dispensing by Age and Drug Class • Resources: PDMP forms moved to AccessGov online submission • Training Materials: Medical Coordinator User Guide <p>Systemic Updates</p> <ul style="list-style-type: none"> • Website Updates pursuant to Title II of Americans with Disabilities Act • Automated Email Notifications
<p>R33.29 March 2026</p>	<p>DEA -> NPI Systemic Changeover</p> <ul style="list-style-type: none"> • Admin Tool: Unique Prescriber Query • Medical Coordinators user interface updates • Dispensing Practitioner account registration updates <p>Administration</p> <ul style="list-style-type: none"> • Non-prescriber account profile changes are routed through Admin for Approval • Password rules and help text are matching across different areas of the system
<p>R33.28 February 2026</p>	<p>DEA -> NPI Systemic Changeover</p> <ul style="list-style-type: none"> • NPI field added for Detailed Prescriber Monitoring Report • Enabling pharmacies to void/revise records submitted with DEA prior to the enforcement of NPI requirements <p>User Interface</p> <ul style="list-style-type: none"> • All Users: Updates to username help text • Pharmacy: Updates to Void/Revise screen • Non-prescribing Healthcare Professionals: Fixes for NPI requirement error for registration and query access <p>Website Updates pursuant to Title II of Americans with Disabilities Act</p>
<p>R33.27 January 2026</p>	<p>DEA -> NPI Systemic Changeover</p> <ul style="list-style-type: none"> • LE/Gov Dispenser Query Redesign <p>User Interface</p> <ul style="list-style-type: none"> • Void/Revise screen instruction updates • Expire Old Errors (before 1/1/2025) <p>Administration</p> <ul style="list-style-type: none"> • Display of Additional DEA Numbers of Prescribers for admin

	<ul style="list-style-type: none"> Fix for November 2025 Dispenser Compliance Report Error BadgerTraCS Law Enforcement Reports Ingestion: fixes for API connection & test data transmission errors
R33.26 December 2025	Dummy NPI fixes to accept controlled substance & compound drug records Password reset fixes for Healthcare Professional accounts with no DEA on file Enabling Medical Coordinator account upload practitioner list by NPI
R33.25 December 2025	Data System: <ul style="list-style-type: none"> Dummy NPI of 9999999999 enabled Dummy NPI dispenser report available for admin User Interface: <ul style="list-style-type: none"> Pharmacy: Revise/Void screen updated to NPI entry Pharmacy: Allow voided/revised without a DEA (for non-scheduled monitored drugs, i.e., Gabapentin) Automated Notification: <ul style="list-style-type: none"> Updated language for Delegate and Medical Coordinator Assistant activation email
R33.24 October 2025	User Interface Updates: <ul style="list-style-type: none"> Submitter: Remove Old Pharmacy Error Logs Law Enforcement/Government Employee: Data Request Attestation Filename Criteria Language Update Website Management: <ul style="list-style-type: none"> Delegate and Medical Coordinator Assistant Activation Email updates User's First Name Updates to Reflect Name in License
R33.23 September 2025	User Interface Updates: <ul style="list-style-type: none"> Submitter: Update Manual Prescription Entry to ASAP4.2B Submitter: Remove Old Pharmacy Error Logs Dispensing Practitioner: account registration NPI field ready for entry Website Management: <ul style="list-style-type: none"> Patient Matching Processing Job Enhancement Patient's Gender on the Patient Report to pull in the Gender from the Most Recent Dispensing Admin Portal: Territories Added to inter-State Query Services Configuration Screen
R33.22 August 2025	DEA -> NPI Systemic Changeover <ul style="list-style-type: none"> NPI information auto-populated on the Record Entry screen for Pharmacy and Dispensing Practitioner account types Erroneously flagged errors of historical records removed from pharmacy error logs Administration Dispenser Report workflow fixes for Law Enforcement or Government user

<p>R33.21 July 2025</p>	<p>DEA -> NPI Systemic Changeover</p> <ul style="list-style-type: none"> • Dispenser Compliance Report reverted to using DEA first, switching to NPI on 12/1 • Pharmacy Zero Report auto populates NPI or leaves blank if account profile doesn't Include NPI • Data Submitter Guide updates <p>Administration Fixes for Detailed Prescriber Monitoring Report</p> <p>User Interface</p> <ul style="list-style-type: none"> • Dispenser Report download fixes for Law Enforcement or Government user • Submission data field PHA05 (Pharmacy Address 1) now accepts up to 55 characters
<p>R33.20 June 2025</p>	<p>Website changes adapting to NPI Requirements Automated Notification Language Updates:</p> <ul style="list-style-type: none"> • Submission compliance notification when NPI is missing • Gabapentin reporting guideline updates <p>User Portal</p> <ul style="list-style-type: none"> • Healthcare Professional Account – NPI requirement pop up updates • Law enforcement/investigative unit account: NPI added to prescriber and dispenser report request screen for <p>Data Analytics</p> <ul style="list-style-type: none"> • Metrics calculations revert to DEA-based
<p>R33.19 May 2025</p>	<p>Website changes adapting to NPI Requirements Data Analytics</p> <ul style="list-style-type: none"> • NPI Search Added to Detailed Prescriber Monitoring Report • NPI Added to Opioid Prescribing Practice Summary Report <p>Admin Portal Fixes and Updates</p>
<p>R33.18 April 2025</p>	<p>Website Administration:</p> <ul style="list-style-type: none"> • On-going Formatting and Calculation cleanups for automated Reports • NPI data field added to reports <p>User Portal: NPI field added to search screen (for law enforcement, prosecutorial, and regulatory agencies)</p>
<p>R33.17 March 2025</p>	<p>User Portal:</p> <ul style="list-style-type: none"> • Additional DEA fields in Prescribers account profile • NPI field added in Pharmacy account profile
	<p>Data Analytics Updates:</p> <ul style="list-style-type: none"> • MME Conversion Factors updates

<p>R33.16 February 2025</p>	<ul style="list-style-type: none"> • Buprenorphine exclusion rules applied to automated reporting of prescribing reports <p>User Interface Updates</p> <ul style="list-style-type: none"> • Healthcare Professionals - MME Calculator & Addiction Resource Updates • Investigators - Dispenser Report Request via User Accounts <p>Administrative workflow updates - NPI added to Pending Account Registration Review</p> <p>Webpage Language Updates: Registration Page, Dashboard charts</p>
<p>R33.15.1 February 2025</p>	<p>Emergency Release to fix errors for out of state queries connecting via PMPi hub</p>
<p>R33.15 January 2025</p>	<p>Data Analytics Updates:</p> <ul style="list-style-type: none"> • New admin tool of adding additional DEA numbers to automate Detailed Prescriber Monitoring Report • Formatting updates on Opioid Practice Summary Report <p>User Interface Updates:</p> <ul style="list-style-type: none"> • Pharmacy Account data revise/edit screen now with multiple DEAs dropdown selection
<p>R33.14 January 2025</p>	<p>Updates to online form “Report Suspected Errors in WI ePDMP Data” PDF</p> <p>Pharmacy additional DEA display</p> <p>Increased License Number Character Limits from 7 to 8</p> <p>File Processing Updates - Skipping Duplicate Files</p>
<p>R33.13 December 2024</p>	<p>User Interface:</p> <ul style="list-style-type: none"> • Updated Text on the Delegate Management Screen • Updated Calculations for Daily Prescribing Volume Ranking for Opioids • License Number is no Longer a Required Field for a Medical Coordinator Account <p>Admin Portal Updates:</p> <ul style="list-style-type: none"> • Added Submission Date to Prescriber Alerts Table • NDC of Dispensed Medications displayed in the prescriber Report • Updated the Prescriber Query Compliance Report
<p>R33.12 November 2024</p>	<p>ePDMP Webpage Updates: Contact Us info & user registration screen for Medical Coordinator and Researcher</p> <p>Analytics and Reports Updates-</p> <ul style="list-style-type: none"> • Prescriber Monitoring Report Charts Readability • Prescriber Address populated on Dispensing History Details <p>Administrative Workflow Enhancement: Alert reviewing screen updates</p>
<p>R33.11 September 2024</p>	<p>Non – HCP Alert Displays on Requested Reports</p> <p>Detailed Prescriber Monitoring Report Rework</p> <p>Updated Quarterly CSB Reports</p> <p>Prescriber Address Visible on Patient Report Table</p>
<p>R33.10 August 2024</p>	<p>Automation of Reports:</p> <ul style="list-style-type: none"> • Opioid Prescribing Practice Summary Report Review • Quarterly Statistics for CSB Report Review

	<ul style="list-style-type: none"> Detailed Prescriber Monitoring Report Review Prescriber Address Populated on UI EHR Support Partial Refill Review
R33.9 July 2024	Opioid Prescribing Practice Summary Report Review Text Updates in UI Updates to notification emails Prescriber Query Compliance Report update
R33.8 June 2024	Opioid Prescribing Practice Summary Report Review Quarterly CSB Report Review Compound Drug UI Statistic utilization optimizations Addition of email address to non-HCP query requests
R33.7 May 2024	Dispenser Compliance Report Review Submitter/Dispenser Report Review
R33.6 April 2024	System Updates <ul style="list-style-type: none"> Pending Account Changes UI language UAT email notification links Controlled Substance UI language Updated error messages for Submitters RXCheck 3.1 Update and Patch Statistics Dashboard populate counties' logic EHR Support

WI ePDMP Integration Services Summary

Updated 4.27.2026

Pending Health Systems and EHR Platforms	Status			Notes
Internal Medicine Associates	In discussion			
MECFS Clinic MN	In discussion			
CareATC	In discussion			
Connected Health Systems (61% of monthly patient queries)	Free Pricing Model	Implementation Date	Est. Total # of Users	Notes
Advent Health		03/05/2023	15	
Allina Health	Y	09/18/2023	100	
Ascension Wisconsin				
Aspirus Health Care				
Aurora Health Care	Y	05/08/2024	12,000	
Children's Hospital of Wisconsin	Y	09/01/2022	300	
Clark County	Y	11/01/2023		
Clean Slate	Y	09/01/2022	26	
CompuGroup Medical	Y	08/14/2024	50	
DrFirst	Y	05/01/2025		
Froedtert & the Medical College of Wisconsin			100	Pending signed Free agreement
GHC of South Central Wisconsin	Y	09/01/2024		
Gundersen Health System			800	Pending signed Free agreement
HealthPartners				
HSHS / Prevea Health	Y	01/01/2023	500	
M Health Fairview	Y	08/01/2022	30	
Marshfield Clinic	Y	09/01/2022	100	
Mayo Clinic				
Mercy Health	Y	08/01/2022	766	
Monroe Clinic				
NOVO Health Technology Group	Y	02/01/2023		

OakLeaf	Y	6/11/2025	116	
Ochin	Y	12/21/2022	100	
ProHealth Care	Y	1/17/2025		
QuadMed, LLC	Y	5/17/2023	40	
SSM Health				
Thedacare				Pending signed Free agreement
UnityPoint				
UW Health			4000	
Wisconsin Statewide Health Information Network	Y	09/01/2022	3500	

DrFirst Facilities	
Alay Health Team	National Medical Groups
Associated Mental Health Consultants	Northwest Passage
Behavioral Health Services of Racine Co.	Nova Integrated Care LLC
Benjamin S. Gozon MDSC D/B/A Capitol Rehabilitation Clinic	Oak Medical
Best Self Counseling Center	Oral Surgery Associates of Milwaukee
Christian Family Solutions	Orthopedic Hospital of Wisconsin
Curana Health of Wisconsin	Pain Management and Treatment Center
Door County Memorial Hospital	Pediatrics Associates
Dr. Colleen Worth, DNP, APNP	Rainbow Palliative Care
Empower Recovery	Reka Furedi MD
Envision ADHD Clinic	Red Oak Counseling
FAMILY PSYCHIATRIC CARE, LLC	Regional Medical Center
Fort Healthcare	Richland Hospital
GI Associates LLC	Rogers Memorial Hospital
Healthy Minds LLC	RULA-WI
Heartland Hospice	Sauk Prairie Memorial Hospital
Housing Initiatives	Shorewood Behavioral Health
Jonathan Hoerl PMHNP	Third Eye Health
Kelly Pickens	UHS_PA_WI
Lake Superior Community Health Center	University of Wisconsin - Milwaukee
Linc Health Clinic	Watertown Rainbow Hospice

Lifescance Health WI	Wauwatosa Children's Clinic
Madison Recovery Center	Watertown Regional Medical Center
Marshfield Clinic Health System	Yee Xiong MD
Mental Health Specialty Group PA	
Mile Bluff Medical Center	
Milwaukee Medical Associate, SC	
Mindful Healing and Wellness LLC	

2026 WI PDMP Outreach Calendar

MONTH	EVENT	DESCRIPTION	DATES	NOTES
January				
February	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	2/12/2026	Virtual; Quarterly Meeting
March	RxCheck Governance Board Meeting	Board Member-Participant; Interstate PDMP data exchange discussion	3/12/2026	Virtual; Quarterly Meeting
April	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	4/9/2026	Virtual; Quarterly Meeting
May				
June	RxCheck Governance Board Meeting	Board Member-Participant; Interstate PDMP data exchange discussion	6/11/2026	Virtual; Quarterly Meeting
	PMP InterConnect Steering Committee Meeting	Participant; Annual national meeting for PDMP administrators organized by National Association of Boards of Pharmacy (NABP)	6/23-6/24/2026	Mount Prospect, IL
July	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	7/9/2026	Virtual; Quarterly Meeting
August	Wisconsin Substance Use Summit	PDMP Information Booth	8/5-8/6/2026	Green Bay, WI
September	RxCheck Governance Board Meeting	Board Member-Participant; Interstate PDMP data exchange discussion	9/10/2026	Virtual; Quarterly Meeting
October	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	10/8/2026	Virtual; Quarterly Meeting
	NASCSA Conference (National Association of State Controlled Substances Authorities)	Presenter; annual national meeting organized by NASCSA for government controlled substances authority, PDMP and healthcare professionals	10/26-10/29/2026	Portland, ME
November				
December	RxCheck Governance Board Meeting	Board Member-Participant; Interstate PDMP data exchange discussion	12/10/2026	Virtual; Quarterly Meeting